Welcome to our dedicated page for Nuwellis news (Ticker: NUWE), a resource for investors and traders seeking the latest updates and insights on Nuwellis stock.
Nuwellis, Inc. develops and commercializes medical technology for patients with cardiorenal conditions, including Aquadex SmartFlow ultrafiltration therapy for fluid removal in fluid overload. Company news commonly covers financial results, Aquadex software and product updates, patent activity for catheter technology, clinical case studies in pediatric and heart-failure care, medical-meeting participation, commercial territory expansion, and hospital-support initiatives.
Nuwellis, Inc. (Nasdaq: NUWE) reported its first-quarter results for 2021, showing revenue of $1.9 million, an 18% increase year-over-year. The company completed a rebranding from CHF Solutions, Inc. on April 27, 2021. Key highlights include increased Aquadex therapy utilization, the enrollment of the first pediatric patient in a clinical registry, and strong endorsements for a Category III CPT code application. Nuwellis ended the quarter with $27.9 million in cash and no debt, despite a net loss of $5.2 million.
Nuwellis, Inc. (NASDAQ:NUWE), formerly known as CHF Solutions, will announce its first quarter 2021 financial results on May 11, 2021, followed by a conference call at 9:00 AM ET. The session will include discussions on financial outcomes and business overview. Investors can access the live webcast through the company's website. Nuwellis specializes in developing medical devices aimed at alleviating fluid overload through innovative solutions, primarily focused on the Aquadex SmartFlow® system.
Summary not available.